MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

On location

Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis

In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm,...

Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm

Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...
On location

Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib

According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis severity, transfusion dependence, and other symptoms in a cohort of...
On location

Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS

Watch our interview with David Sallman, MD.In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual...

Naveen Pemmaraju: A New Option for Myelofibrosis?

Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
David Sallman, MD

David Sallman: Early Results of 5F9 in AML and MDS

David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...

Five Decades of Experience With MPNs: Characterizing Survival and Outcomes

A report based on data from more than 3,000 patients with myeloproliferative neoplasms (MPNs) evaluated at the Mayo Clinic in Rochester, Minnesota, over 50...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...
On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...

CHIP-Associated Mutations Linked With Comorbidities in MDS

The presence of clonal hematopoiesis of indeterminate potential (CHIP) mutations, particularly DNMT3A and JAK2 mutations, was associated with a higher likelihood of prior myocardial...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.